Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors

Details for Australian Patent Application No. 2004202701 (hide)

Owner Novartis AG The Scripps Research Institute

Inventors Nemerow, Glen R; Von Seggern, Daniel J

Agent Davies Collison Cave

Pub. Number AU-A-2004202701

Parent 24908

Filing date 18 June 2004

Wipo publication date 15 July 2004

International Classifications

C12N 015/861 Mutation or genetic engineering - Adenoviral vectors

C12N 015/34 Mutation or genetic engineering - Proteins from DNA viruses

C12N 005/10 Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

A61K 048/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

Event Publications

1 July 2004 Complete Application Filed

15 July 2004 Application Open to Public Inspection

  Published as AU-A-2004202701

11 May 2006 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004202702-Compositions comprising sympathomimetic amine salts unsuitable for illegal use

2004202700-Central determination gaming system with a keno game